Compare Marsh & McLennan Companies, Inc. (MRSH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B), while State Street SPDR S&P Biotech ETF trades at $153.8 (market cap $10.11B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 8.3× State Street SPDR S&P Biotech ETF's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MRSH | XBI | |
|---|---|---|
Market Cap | $84.31B | $10.11B |
Volume | 3,948,947 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $207.02 | $169.55 |
52-Week Low | $157.32 | $104.99 |
Typical Hold Time | 109 Days | 38 Days |
Enterprise Value | $104.99B | — |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRSH trades at $176.16, up 1.44% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company completed the acquisition of Accel Holdings on October 2, 2026, expanding its advisory footprint. Revenue grew to $27.0B in 2025, with a net income margin of 15.41%, while valuation ratios like P/E of 21.57 and ROE of 25.72% reflect strong profitability. Analysts maintain a consensus price target of $202.71, though sentiment is mixed with a 'Hold' rating from most.
The outlook for MRSH is positive due to earnings momentum and strategic acquisitions, but risks include competitive pressures and potential margin compression. Upside remains if the company meets Q3 2026 EPS expectations of $1.97, supported by solid cash flow trends. Investors should weigh the high P/B ratio of 5.55 against growth prospects in the reinsurance sector.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
